Evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat type 2 diabetes and obesity, not only improve peripheral glucose and lipid metabolism but also cross the blood-brain barrier to exert neuroprotective effects
If those meals arent structured around protein first, you can easily end up consuming far less than your body needs
J Leukoc Biol (2019) 106:30922
Khan Z, Jan R, Asif S, Farooq M, Kim KM
For instance, Novo Nordisk plans to initiate late-stage clinical trials of its experimental obesity drug, amycretin, in both injectable and oral forms during the first quarter of 2026
GLP-1 Receptor Stimulation Preserves Primary Cortical and Dopaminergic Neurons in Cellular and Rodent Models of Stroke and Parkinsonism